NCT01706055View on ClinicalTrials.gov

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)

CompletedOBSERVATIONAL
Enrollment

629

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

March 31, 2016

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Interferon beta-1b (Betaseron, BAY86-5046)

Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY